PMOS Linked to Higher Alzheimer's Risk, Though Metabolic Health Is the Key Factor, Researchers Say
A review published in the Journal of the Endocrine Society in October 2026 found that people with PMOS, formerly known as PCOS, may face a higher risk of Alzheimer's disease and related dementias. Researchers say the link is driven primarily by metabolic conditions like insulin resistance and obesity, not the hormonal profile of PMOS itself.
People with Polyendocrine Metabolic Ovarian Syndrome, or PMOS, may face a higher risk of Alzheimer's disease and related dementias, according to a review published in the Journal of the Endocrine Society in October 2026.
PMOS was formerly known as Polycystic Ovary Syndrome, or PCOS. The medical community updated the name in 2026 to better reflect the condition's metabolic nature.
Researchers analyzed data from studies conducted through October 2025 and found that PMOS patients sometimes show mild impairments in memory and executive function, including challenges with processing speed, planning, and decision-making. Some studies also found elevated levels of Alzheimer's-associated biomarkers in blood tests.
However, the researchers concluded that PMOS does not appear to independently cause Alzheimer's disease. When they compared PMOS patients to metabolically healthy control groups, the neurological differences were significantly less pronounced.
The observed associations are largely attributed to underlying metabolic conditions common in PMOS patients, including obesity, insulin resistance, and cardiovascular risk factors. These conditions are well-established risk factors for Alzheimer's disease on their own.
Experts say patients with PMOS should not be alarmed by the findings. The current evidence does not support routine dementia screening for people based solely on a PMOS diagnosis.
Clinicians recommend that PMOS patients focus on metabolic health management. A Mediterranean-style diet, cardiovascular exercise, and strength training can improve insulin sensitivity and reduce cardiovascular risk. Addressing these factors early may also benefit long-term brain health.
Researchers called for large-scale, long-term studies to determine whether PMOS exerts any direct, independent effect on dementia risk.
